FDA approves talazoparib with enzalutamide for HRR gene …
On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic...
Talazoparib and enzalutamide tied to improved overall survival …
1 day ago · For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is ...
Talazoparib plus enzalutamide in men with first-line metastatic ...
Jul 22, 2023 · We aimed to compare the efficacy and safety of talazoparib (a PARP inhibitor) plus enzalutamide (an androgen receptor blocker) versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Talazoparib + Enzalutamide Tied to Improved Overall Survival in ...
17 hours ago · WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall survival versus placebo + ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary ...
First-line talazoparib with enzalutamide in HRR-deficient …
Dec 4, 2023 · Combining talazoparib with enzalutamide significantly improved radiographic progression-free survival in patients with mCRPC harboring HRR gene alterations, supporting talazoparib plus...
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Feb 13, 2025 · OS in patients without a BRCA alteration was 48.4 months with enzalutamide-talazoparib versus 37.1 months with enzalutamide alone (HR=0.749, 95% CI 0.582-0.963, nominal P=0.0237).
First-line talazoparib with enzalutamide in HRR-deficient …
Jan 24, 2024 · Combining talazoparib with enzalutamide significantly improved radiographic progression-free survival in patients with mCRPC harboring HRR gene alterations, supporting talazoparib plus enzalutamide as a potential first-line treatment for these patients.
Talazoparib Plus Enzalutamide Extends Survival in mCRPC
Feb 13, 2025 · Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk.
Talazoparib Combo Prolongs Survival in Mets Prostate Cancer
6 days ago · Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
Talazoparib Combo Approved for Metastatic Prostate Cancer
Aug 4, 2023 · FDA based the approval of enzalutamide (Xtandi) plus talazoparib (Talzenna) on a large clinical trial that showed the combination was more effective than enzalutamide alone in treating men with metastatic castration-resistant prostate cancer.
- Some results have been removed